The cerebrovascular activity of 5-hydroxyadamantan-2-one succinic acid ester not only in ischemic brain injury but also in a more severe form of vascular damage to the body such as combined pathology (experimental myocardial infarction with subsequent global transient cerebral ischemia) was demonstrated experimentally in rats. The reference drug 5-hydroxyadamantan-2-one tested on combined vascular pathology more significantly lowered the level of arterial pressure, in contrast to experiments with cerebral ischemia. This entailed a decrease in the blood supply to the brain resulting from impaired autoregulation of cerebral circulation. Thus, the hypotensive effect of 5-hydroxyadamantan-2-one was transformed into a hypertensive effect by including a succinic acid moiety into its molecule. This effect was most pronounced when modeling combined vascular pathology of the brain and heart. The reference drug and to a much lesser extent 5-hydroxyadamantan-2-one succinic acid ester reduced the level of blood supply to the brain in experimental myocardial infarction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. V. Kurza, N. I. Avdyunina, T. S. Gan’shina, et al., Khim-farm. Zh., 52(2), 3 – 7 (2018); https://doi.org/10.30906/0023-1134-2018-52-2-3-7; Pharm. Chem. J., 52(2), 103 – 107 (2018); https://doi.org/10.1007/s11094-018-1772-y.
R. S. Mirzoyan, A. V. Topchyan, M. I. Timkina, and M. G. Balasanyan, Eksp. Klin. Farmakol., 62, No. 5, 11 – 14 (1999).
T. S. Gan’shina, E. V. Kurza, E. V. Vasil’eva, et al., Eksp. Klin. Farmakol., 83(6), 3 – 7 (2020); https://doi.org/10.30906/0869-2092-2020-83-6-3-7.
T. S. Gan’shina, I. N. Kurdyumov, E. V. Kurza, et al., Eksp. Klin. Farmakol., 83(1), 3 – 6 (2020); https://doi.org/10.30906/0869-2092-2020-83-1-3-6.
J. S. Saczynski, F. A. Spencer, J. M. Gore, et al., Arch. Intern. Med., 168(19), 2104 – 2110 (2008).
T. Gunnoo, N. Hasan, M. S. Khan, et al., BMJ Open., 6(1), e009535 (2016); https://doi.org/10.1136/bmjopen-2015-009535.
R. Bhatia, G. Sharma, C. Patel, et al., J. Stroke Cerebrovasc. Dis., 28(12), 104400 (2019); https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104400.
A. Albaeni, C. M. Harris, H. Nasser, et al., Int. J. Cardiol. Heart Vasc., 31, 100684 (2020); https://doi.org/10.1016/j.ijcha.2020.100684.
G. Aggarwal, S. H. Patlolla, S. Aggarwal, et al., J. Am. Heart Assoc., 10(2), e017693 (2021); https://doi.org/10.1161/JAHA.120.017693.
R. S. Mirzoyan, T. S. Gan’shina, N. A. Khailov, et al., Eksp. Klin. Farmakol., 77(3), 3 – 8 (2014).
R. S. Mirzoyan, M. B. Plotnikov, T. S. Gan’shina, et al., Handbook for Preclinical Drug Studies [in Russian], Part 1, Grif i K, Moscow (2012), pp. 480 – 487.
I. M. Seropian and G. E. Gonzales, in: Experimental Surgical Models in the Laboratory Rat, A. Rigalli and V. E. Di Loreto (eds.), CRC Press, Taylor & Francis Group, Boca Raton, London, New York (2009), pp. 201 – 204.
M. A. Lebedeva, Yu. S. Medvedeva, R. S. Mirzoyan, et al., Patol. Fiziol. Eksp. Ter., 4, 35 – 40 (2013).
R. S. Mirzoyan, T. S. Gan’shina, D. V. Maslennikov, et al., Eksp. Klin. Farmakol., 75(6), 27 – 30 (2012).
R. S. Mirzoyan, T. S. Gan’shina, D. V. Maslennikov, et al., BioMed Res. Int., 2014, Art. ID 586501, 8 pp (2014); https://doi.org/10.1155/2014/586501.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 56, No. 2, pp. 13 – 16, February, 2022.
Rights and permissions
About this article
Cite this article
Gan’shina, T.S., Kurza, E.V., Maslennikov, D.V. et al. Cerebrovascular Efficacy of 5-Hydroxyadamantan-2-One Succinic Acid Ester in Combined Vascular Pathology of Brain and Heart. Pharm Chem J 56, 155–158 (2022). https://doi.org/10.1007/s11094-022-02614-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-022-02614-1